Abstract
Bone morphogenetic protein-2 (BMP-2) is used to promote bone regeneration. However, the bone regeneration ability of BMP-2 relies heavily on the delivery vehicle. Previously, we have developed heparin-conjugated fibrin (HCF), a vehicle for long-term delivery of BMP-2 and demonstrated that long-term delivery of BMP-2 enhanced its osteogenic efficacy as compared to short-term delivery at an equivalent dose. The aim of this study was to compare the bone-forming ability of the BMP-2 delivered by HCF to that delivered by clinically utilized BMP-2 delivery vehicle collagen sponge. An in vitro release profile of BMP-2 showed that HCF released 80% of the loaded BMP-2 within 20 days, whereas collagen sponge released the same amount within the first 6 days. Moreover, the BMP-2 released from the HCF showed significantly higher alkaline phosphatase activity than the BMP-2 released from collagen sponge at 2 weeks in vitro. Various doses of BMP-2 were delivered with HCF or collagen sponge to mouse calvarial defects. Eight weeks after the treatment, bone regeneration was evaluated by computed tomography, histology, and histomorphometric analysis. The dose of BMP-2 delivered by HCF to achieve 100% bone formation in the defects was less than half of the BMP-2 dose delivered by collagen sponge to achieve a similar level of bone formation. Additionally, bone regenerated by the HCF-BMP-2 had higher bone density than bone regenerated by the collagen sponge-BMP-2. These data demonstrate that HCF as a BMP-2 delivery vehicle exerts better osteogenic ability of BMP-2 than collagen sponge, a clinically utilized delivery vehicle.
Highlights
The application of bone morphogenetic proteins (BMPs) has recently emerged as an effective treatment in bone reconstruction surgery (Friedlaender, 2004; Termaat et al, 2005)
80% of the Bone morphogenetic protein-2 (BMP-2) loaded on the collagen sponge was released over a period of 6 days, whereas the same dose of BMP-2 was released from the heparin-conjugated fibrin (HCF) over a period of 20 days
The aim of this study was to compare HCF and collagen sponge, which is a product that is currently used in clinical applications, as BMP-2 delivery vehicles for bone formation
Summary
The application of bone morphogenetic proteins (BMPs) has recently emerged as an effective treatment in bone reconstruction surgery (Friedlaender, 2004; Termaat et al, 2005). There are several limitations in the clinical application of BMPs. Firstly; BMP-2 may lose its bioactivity due to its short half-life (Takahashi et al, 2005). A large dose of BMP-2 is required for clinical treatment due to its rapid loss through diffusion (Carter et al, 2008). Such limitations require large doses of BMP-2 to be used clinically, resulting in high treatment costs and undesirable side effects including bone over-
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
